Belgium’s Confo Therapeutics gains its first big pharma partner in the field of non-opioid pain treatment, giving the big pharma will test its master protocol approach as it put its R&D muscle behind this major area of unmet need.

The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.

As Australia ends a resources boom, a decline in manufacturing has left the country vulnerable, and a concerted investment in biotechnology could transform the country, according to a new report.

Quartet Medicine Inc.'s pipeline of novel small-molecule drugs to address chronic pain and inflammation target the tetrahydrobiopterin (BH4) synthesis pathway, a target with genetic and pharmacological links to regulating human disease at the intersection of the peripheral nervous system and the immune system. The start-up thinks its approach has the potential to provide improved efficacy without the side effects associated with existing centrally acting analgesics.